- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01417091
Safety, Pharmacokinetics and Pharmacodynamics of BPS804 in Osteogenesis Imperfecta
A Randomized, Open Label Intra-patient Dose Escalation Study With an Untreated Reference Group to Evaluate Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Infusions of BPS804 in Adults With Moderate Osteogenesis Imperfecta
This is a randomized, open label intra-patient dose escalation study to evaluate safety and tolerability, pharmacokinetics, and pharmacodynamics of BPS804 in adults with osteogenesis imperfecta (OI).
Pharmacodynamic effect will be determined by serological biomarkers and radiologic assessments. In addition, tolerability and pharmacokinetics (PK) will be evaluated.
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Bruxelles, Belgium, 1200
- Novartis Investigative Site
-
Gent, Belgium, 9000
- Novartis Investigative Site
-
-
-
-
Quebec
-
Montreal, Quebec, Canada, H3GIA6
- Novartis Investigative Site
-
-
-
-
-
Wuerzburg, Germany, 97074
- Novartis Investigative Site
-
-
-
-
California
-
Anaheim, California, United States, 92801
- Novartis Investigative Site
-
-
Florida
-
Miramar, Florida, United States, 33025
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Osteogenesis imperfecta
- Two or more previous fractures
- Bone mineral density Z-score of ≤ -1.0 and > -4.0
Exclusion Criteria:
- Open epiphyses
- Fracture within last 2 weeks
- Treatment with bisphosphonates/teriparatide (last 6 months)
- Surgery within last year
Other protocol-defined inclusion/exclusion criteria may apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment group
|
|
No Intervention: Untreated reference group
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability (composite outcome: standard laboratory, (serious) adverse events)
Time Frame: Day 1 through 141
|
The assessment of safety will be based on primarily on the frequency of adverse events, laboratory abnormalities, and serious adverse events suspected by the investigators to be related to study treatments.
The AE collection period extends from the time of first study drug administration drug until study completion.
The intensity of each AE will be characterized and classified into 1 of the 3 generic categories (mild, moderate, or severe).
The number and percentage of patients with adverse events will be tabulated by treatment group, body system and preferred term.
The periods for adverse event tabulation will be from dose administration up to next dose administration if a further dose is given, and from dose administration to EOS for the last dose administration of a patient.
|
Day 1 through 141
|
Determination of pharmacodynamic effect by means of biomarkers
Time Frame: Day 1 and Day 43
|
Biomarker data from serum bone formation biomarkers: procollagen type I N-terminal propeptide, procollagen type I C-terminal propeptide, osteocalcin, and bone-specific alkaline phosphatase, and from serum bone resporption mbiomarkers: C-telopeptides of type I collagen cross-links, and N-telopeptides of type I collagen cross-links will be reported as concentration results, measured using a specific assay with a working range defined by the Lower limit of quantification and Upper limit of quantification.
It will be considered a sign for efficacy, if any of the above show significant (2-sided, alpha=0.05)
increase versus baseline in the BPS804 group on day 43.
|
Day 1 and Day 43
|
Change in Z-score from baseline to Day 141
Time Frame: Day 1 and Day 141
|
Bone mineral density will be assessed by dual-energy X-ray absorptiometry of the lumbar spine.
Analysis will include four vertebral levels from L1 to L4.
Individual vertebral levels may be excluded due to artifact.
Bone mineral density Z-scores will be used as these are a comparison of a patient's BMD to that of a patient of the same age, sex, and ethnicity.
The comparison of change from baseline with the matching change in the reference group will be done by 2-sample t-tests (1-sided).
It will be considered a sign for efficacy, if any of the above show significant (2-sided, alpha=0.05)
increase versus baseline in the BPS804 group on day 141.
|
Day 1 and Day 141
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determination of the serum concentration-time profiles of BPS804
Time Frame: Day 1 (prior to administration and 3x after administration) and Days 2, 8, 15 (2x), 16, 29 (4x), 30, 36, 43, 57, 85, 113,141
|
Individual and overlaying individual serum concentration-time profiles of BPS804 will be constructed from the serial sampling on Day 1 (prior to administration and 3x after administration) and Days 2, 8, 15 (2x), 16, 29 (4x), 30, 36, 43, 57, 85, 113,141.
In addition arithmetic and geometric mean serum concentration-time profiles of BPS804 will be constructed from the above data points.
|
Day 1 (prior to administration and 3x after administration) and Days 2, 8, 15 (2x), 16, 29 (4x), 30, 36, 43, 57, 85, 113,141
|
Determination of the area under the serum concentration-time curve from time zero to the end of the dosing interval tau after the first dose
Time Frame: Day 1 (prior to administration and 3x after administration) and Days 2, and 8
|
The area under the serum concentration-time curve from time zero to the end of the dosing interval tau after the first dose will be derived using using non-compartmental methods from data collected on Day 1 (4x) and Days 2, and 8.
|
Day 1 (prior to administration and 3x after administration) and Days 2, and 8
|
Determination of the maximal concentration after the first dose
Time Frame: Day 1 (prior to administration and 3x after administration) and Days 2, and 8
|
The maximal concentration after the first dose will be derived using using non-compartmental methods from data collected Day 1 (4x) and Days 2, and 8.
|
Day 1 (prior to administration and 3x after administration) and Days 2, and 8
|
Determination of the time of maximal concentration after the first dose
Time Frame: Day 1 (prior to administration and 3x after administration) and Days 2, and 8
|
The time of maximal concentration after the first dose will be derived using using non-compartmental methods from data collected Day 1 (4x) and Days 2, and 8.
|
Day 1 (prior to administration and 3x after administration) and Days 2, and 8
|
Determination of the maximal concentration after the second dose
Time Frame: Day 15 (prior to administration and 1x after administration) and Day 16
|
The maximal concentration after the second dose will be derived using using non-compartmental methods from data collected from days 15 (2x) and 16.
|
Day 15 (prior to administration and 1x after administration) and Day 16
|
Determination of the time of maximal concentration after the second dose
Time Frame: Day 15 (prior to administration and 1x after administration) and Day 16
|
The time of maximal concentration after the second dose will be derived using using non-compartmental methods from data collected from days 15 (2x) and 16.
|
Day 15 (prior to administration and 1x after administration) and Day 16
|
Determination of the area under the serum concentration-time curve from time zero to infinity after the third dose
Time Frame: Days 29 (prior to administration and 3x after administration) and 30, 36, 43, 57, 85, 113, and 141
|
The area under the serum concentration-time curve from time zero to the end of the dosing interval tau after the third dose will be derived using non-compartmental methods from data collected on Days 29 (4x), 30, 36, 43, 57, 85, 113, and 141.
|
Days 29 (prior to administration and 3x after administration) and 30, 36, 43, 57, 85, 113, and 141
|
Determination of the area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration after the third dose
Time Frame: Days 29 (prior to administration and 3x after administration) and 30, 36, 43, 57, 85, 113, and 141
|
The area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration after the third dose will be derived using non-compartmental methods from data collected on Days 29 (4x), 30, 36, 43, 57, 85, 113, and 141.
|
Days 29 (prior to administration and 3x after administration) and 30, 36, 43, 57, 85, 113, and 141
|
Determination of the area under the serum concentration-time curve from time zero to the end of the dosing interval tau after the third dose
Time Frame: Days 29 (prior to administration and 3x after administration) and 30, 36, 43, 57, 85, 113, and 141
|
The area under the serum concentration-time curve from time zero to the end of the dosing interval tau after the third dose will be derived using non-compartmental methods from data collected on Days 29 (4x), 30, 36, 43, 57, 85, 113, and 141.
|
Days 29 (prior to administration and 3x after administration) and 30, 36, 43, 57, 85, 113, and 141
|
Determination of the maximal serum concentration after the third dose
Time Frame: Days 29 (prior to administration and 3x after administration) and 30, 36, 43, 57, 85, 113, and 141
|
The maximal serum concentration after the third dose will be derived using using non-compartmental methods from data collected on Days 29 (4x), 30, 36, 43, 57, 85, 113, and 141.
|
Days 29 (prior to administration and 3x after administration) and 30, 36, 43, 57, 85, 113, and 141
|
Determination of the time of maximal concentration after the third dose
Time Frame: Days 29 (prior to administration and 3x after administration) and 30, 36, 43, 57, 85, 113, and 141
|
The time of maximal concentration after the third dose will be derived using using non-compartmental methods from data collected on Days 29 (4x), 30, 36, 43, 57, 85, 113, and 141.
|
Days 29 (prior to administration and 3x after administration) and 30, 36, 43, 57, 85, 113, and 141
|
Determination of the terminal elimination half-life after the third dose
Time Frame: Days 29 (prior to administration and 3x after administration) and 30, 36, 43, 57, 85, 113, and 141
|
The terminal elimination half-life after the third dose will be derived from data collected on Days 29 (4x), 30, 36, 43, 57, 85, 113, and 141 using a compound-specific modeling approach.
|
Days 29 (prior to administration and 3x after administration) and 30, 36, 43, 57, 85, 113, and 141
|
Determination of the concentration of total sclerostin in serum
Time Frame: Screening, Days 1, 8, 15, 29, 36, 43, 57, 85, 113, 141
|
The function of sclerostin is described as an endogenous negative regulator of bone formation.
Total serum sclerostin will be measured from samples collected at screening and on days 1, 8, 15, 29, 36, 43, 57, 85, 113, and 141
|
Screening, Days 1, 8, 15, 29, 36, 43, 57, 85, 113, 141
|
Immunogenicity evaluation in serum
Time Frame: Days 1, 29, 85, and 141
|
Immunogenicity will only be assessed in patients randomized to the treatment group.
Anti-BPS804 antibodies will be measured in human serum on Days 1, 29, 85, and 141 An immunogenicity positive patient at end of study will be followed up until anti-BPS804 antibody levels are back to levels measured on Day 1.
|
Days 1, 29, 85, and 141
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CBPS804A2201
- 2011-001465-41 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteogenesis Imperfecta
-
Nationwide Children's HospitalCompletedOsteogenesis Imperfecta Type III | Osteogenesis Imperfecta Type IIUnited States
-
Ultragenyx Pharmaceutical IncMereo BioPharmaCompletedOsteogenesis Imperfecta Type III | Osteogenesis Imperfecta Type IV | Osteogenesis Imperfecta, Type IUnited States, Canada, Denmark, France, United Kingdom
-
Emory UniversityNot yet recruitingOsteogenesis Imperfecta | Osteogenesis Imperfecta Type III
-
Novartis PharmaceuticalsCompletedOsteogenesis ImperfectaUnited States
-
Shriners Hospitals for ChildrenNovartisCompleted
-
AmgenTerminatedOsteogenesis Imperfecta (OI)Canada, Czechia, Spain, United Kingdom, United States, Italy, Hungary, Australia, Belgium, France, Germany, Poland
-
Istituto Ortopedico RizzoliRecruitingOsteogenesis ImperfectaItaly
-
Baylor College of MedicineRecruiting
-
SanofiRecruitingOsteogenesis ImperfectaUnited States, Australia, Canada, France
-
Ultragenyx Pharmaceutical IncMereo BioPharmaRecruitingOsteogenesis ImperfectaUnited States, Canada, Turkey, Argentina, Germany, Australia, Italy, Portugal, United Kingdom, Poland, France, Netherlands
Clinical Trials on BPS804
-
Ultragenyx Pharmaceutical IncNovartis; Mereo BioPharmaWithdrawnChronic-kidney Disease Stage 5D on Stable Hemodialysis
-
Ultragenyx Pharmaceutical IncNovartis; Mereo BioPharmaCompleted
-
Ultragenyx Pharmaceutical IncMereo BioPharmaWithdrawnOsteogenesis ImperfectaUnited States
-
Ultragenyx Pharmaceutical IncMereo BioPharmaTerminatedOsteogenesis ImperfectaUnited States
-
Ultragenyx Pharmaceutical IncNovartis; Mereo BioPharmaCompletedOsteoporosis | OsteopeniaUnited States
-
Ultragenyx Pharmaceutical IncRecruitingOsteogenesis ImperfectaUnited States, Canada, Germany, France, Poland, Netherlands, Italy, Brazil
-
Ultragenyx Pharmaceutical IncMereo BioPharmaRecruitingOsteogenesis ImperfectaUnited States, Canada, Turkey, Argentina, Germany, Australia, Italy, Portugal, United Kingdom, Poland, France, Netherlands
-
Ultragenyx Pharmaceutical IncMereo BioPharmaCompletedOsteogenesis Imperfecta Type III | Osteogenesis Imperfecta Type IV | Osteogenesis Imperfecta, Type IUnited States, Canada, Denmark, France, United Kingdom
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedGastric CancerUnited States